Literature DB >> 29589641

Cutaneous squamous cell carcinoma complicating hidradenitis suppurativa: a review of the prevalence, pathogenesis, and treatment of this dreaded complication.

Stephanie Chapman1, Daniel Delgadillo1, Cara Barber1, Amor Khachemoune2,3.   

Abstract

Hidradenitis suppurativa (HS) is a chronic and debilitating skin disorder characterized by the formation of painful abscesses, draining sinus tracts, and scarring, predominantly in skin folds such as the axillae and the perineum. The exact prevalence of HS is unknown because the disease is often underreported, but it has been estimated to be as high as 4.1%. HS is three times more prevalent in women than in men. Various comorbidities have been associated with HS, including inflammatory bowel disease and squamous cell carcinoma (SCC). The transformation of chronic HS to SCC is often considered the most severe complication of HS. The prevalence of SCC associated with HS is approximately 4.6%, and is more common among men. It is likely that the chronic irritation and inflammation characteristic of HS drive the malignant transformation to SCC, and recent work has identified other potential risk factors for this malignant transformation, including human papillomavirus (HPV) infection and tobacco use. Treatment modalities have expanded in recent years to include triple antibiotic therapy, immunomodulatory biologic agents, laser therapy, and surgical excision. Knowledge of these comorbid associations of HS, especially the malignant transformation to SCC, is highly important for the management and follow-up of this chronic disease.

Entities:  

Mesh:

Year:  2018        PMID: 29589641

Source DB:  PubMed          Journal:  Acta Dermatovenerol Alp Pannonica Adriat        ISSN: 1318-4458


  9 in total

1.  Risk of keratinocyte carcinoma among patients with hidradenitis suppurativa.

Authors:  S Ashrafzadeh; Y Kim; G A Peters; H Lee; M M Asgari
Journal:  Br J Dermatol       Date:  2020-07-09       Impact factor: 9.302

Review 2.  Hidradenitis suppurativa.

Authors:  Robert Sabat; Gregor B E Jemec; Łukasz Matusiak; Alexa B Kimball; Errol Prens; Kerstin Wolk
Journal:  Nat Rev Dis Primers       Date:  2020-03-12       Impact factor: 52.329

3.  Vulvar squamous cell carcinoma complicating hidradenitis suppurativa in a young woman.

Authors:  Marine Sevray; Pierre-François Dupré; Glen Le Flahec; Alexandra Trimaille; Laurent Misery; Emilie Brenaut
Journal:  JAAD Case Rep       Date:  2019-10-31

4.  Giant Squamous Cell Carcinoma on Chronic Lichen Planus on the Ankle - A Case Report and Short Literature Review.

Authors:  Uwe Wollina; Claudia Krönert; Jacqueline Schönlebe; Aleksandra Vojvodic; Torello Lotti
Journal:  Open Access Maced J Med Sci       Date:  2019-08-19

5.  Questionnaire-based epidemiological study of hidradenitis suppurativa in Japan revealing characteristics different from those in Western countries.

Authors:  Koremasa Hayama; Hideki Fujita; Takashi Hashimoto; Tadashi Terui
Journal:  J Dermatol       Date:  2020-05-22       Impact factor: 4.005

6.  Invasive Cutaneous Squamous Cell Carcinoma Arising from Chronic Hidradenitis Suppurativa: A Case Report of Treatment by Slow Mohs Micrographic Surgery.

Authors:  Seung-Ju Lee; Jung Min Lim; Si-Hyung Lee; Kee Yang Chung; Mi Ryung Roh
Journal:  Ann Dermatol       Date:  2020-12-30       Impact factor: 1.444

7.  The management of hidradenitis suppurativa degenerating into squamous cell carcinoma: About three case reports.

Authors:  Souhaib Atri; Ahmed Ben Mahmoud; Alia Zehani; Amine Chammakhi; Wael Rebai; Montasser Jameleddine Kacem
Journal:  Ann Med Surg (Lond)       Date:  2021-03-24

8.  A complication in a patient with hidradenitis suppurativa taking adalimumab.

Authors:  Olivia D Perez; Meera Tarazi; Sameera Husain; Jasnit Makkar; Stephanie M Gallitano
Journal:  JAAD Case Rep       Date:  2022-07-05

9.  Vulvar cancer in hidradenitis suppurativa.

Authors:  T F M Vergeldt; R J B Driessen; J Bulten; T H J Nijhuis; J A de Hullu
Journal:  Gynecol Oncol Rep       Date:  2022-01-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.